The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis

International Journal of Cardiology

Volumn 180, Issue , 2015, Pages 185-191

  Lee, Seung Jun ^a   Uhm, Jae Sun ^a   Kim, Jong Youn ^a   Pak, Hui Nam ^a   Lee, Moon Hyoung ^a   Joung, Boyoung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Atrial fibrillation; Hemorrhage; Liver cirrhosis; Oral anticoagulant; Stroke; Vitamin K antagonist

Indexed keywords

ANTIVITAMIN K; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR DISEASE; CHILD PUGH SCORE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HAS BLED SCORE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; ONSET AGE; RETROSPECTIVE STUDY; RISK REDUCTION; SCORING SYSTEM; THROMBOEMBOLISM; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COMPLICATION; FOLLOW UP; HEMORRHAGE; MIDDLE AGED; PROSPECTIVE STUDY; RISK ASSESSMENT; SOUTH KOREA;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK ASSESSMENT; VITAMIN K;

EID: 84920524068     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.11.183     Document Type: Article

References (43)

1. S. Stewart, C.L. Hart, D.J. Hole, and J.J. McMurray Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study Heart 86 2001 516 521
2. A.S. Go, E.M. Hylek, and K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
3. K.L. Furie, S.E. Kasner, and R.J. Adams Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 42 2011 227 276
4. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
5. C.W. Siu, and H.F. Tse Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation Circ. Arrhythm Electrophysiol. 7 2014 300 306
6. S. Vong, and B.P. Bell Chronic liver disease mortality in the United States, 1990-1998 Hepatology 39 2004 476 483
7. C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect. Dis. 5 2005 558 567
8. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576
9. J. Tomoda, M. Mizuno, T. Sugihara, T. Itano, and T. Tsuji Gastric mucosal lesion in liver disease: impaired gastric mucosal defence mechanism in rats with induced liver injury and in patients with liver cirrhosis J. Gastroenterol. Hepatol. 4 Suppl. 1 1989 136 139
10. J.C. Luo, H.B. Leu, and M.C. Hou Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study Aliment. Pharmacol. Ther. 36 2012 542 550
11. H. Niizuma, J. Suzuki, T. Yonemitsu, and T. Otsuki Spontaneous intracerebral hemorrhage and liver dysfunction Stroke 19 1988 852 856
12. Y. Fujii, S. Takeuchi, R. Tanaka, T. Koike, O. Sasaki, and T. Minakawa Liver dysfunction in spontaneous intracerebral hemorrhage Neurosurgery 35 1994 592 596
13. B.F. Gage, Y. Yan, and P.E. Milligan Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am. Heart J. 151 2006 713 719
14. A. Rash, T. Downes, R. Portner, W.W. Yeo, N. Morgan, and K.S. Channer A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO) Age Ageing 36 2007 151 156
15. P.T. Akins, H.A. Feldman, and R.G. Zoble Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials Stroke 38 2007 874 880
16. A.S. Go, E.M. Hylek, L.H. Borowsky, K.A. Phillips, J.V. Selby, and D.E. Singer Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann. Intern. Med. 131 1999 927 934
17. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 2009 1139 1151
18. P. Petersen, G. Boysen, J. Godtfredsen, E.D. Andersen, and B. Andersen Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study Lancet 1 1989 175 179
19. H.G. Site Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
20. H. Decousus, V.F. Tapson, and J.F. Bergmann Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators Chest 139 2011 69 79
21. M.G. Delgado, S. Seijo, and I. Yepes Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis Clin. Gastroenterol. Hepatol. 10 2012 776 783
22. K.I. Rodriguez-Castro, P. Simioni, P. Burra, and M. Senzolo Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis Liver Int. 32 2012 1465 1476
23. S.D. Berkowitz, D.C. Sane, and K.N. Sigmon Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group J. Am. Coll. Cardiol. 32 1998 311 319
24. M.H. Tsai, Y.S. Peng, and Y.C. Chen Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock Hepatology 43 2006 673 681
25. U. Heemann, U. Treichel, and J. Loock Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study Hepatology 36 2002 949 958
26. L. Sandrin, B. Fourquet, and J.M. Hasquenoph Transient elastography: a new noninvasive method for assessment of hepatic fibrosis Ultrasound Med. Biol. 29 2003 1705 1713
27. J. Foucher, E. Chanteloup, and J. Vergniol Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study Gut 55 2006 403 408
28. G.Y. Lip, and S.J. Edwards Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis Thromb. Res. 118 2006 321 333
29. H.D. White, M. Gruber, and J. Feyzi Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V Arch. Intern. Med. 167 2007 239 245
30. D.B. Matchar, A. Jacobson, and R. Dolor Effect of home testing of international normalized ratio on clinical events N. Engl. J. Med. 363 2010 1608 1620
31. S.J. Connolly, J.W. Eikelboom, and J. Ng Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable Ann. Intern. Med. 155 2011 579 586
32. F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, and E. Briet A method to determine the optimal intensity of oral anticoagulant therapy Thromb. Haemost. 69 1993 236 239
33. E.M. Hylek, A.S. Go, and Y. Chang Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N. Engl. J. Med. 349 2003 1019 1026
34. S.J. Connolly, J. Pogue, and J. Eikelboom Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 2008 2029 2037
35. A. Berzigotti, A. Bonfiglioli, and A. Muscari Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis Liver Int. 25 2005 331 336
36. J.B. Olesen, G.Y. Lip, and M.L. Hansen Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study BMJ 342 2011 d124
37. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
38. European Heart Rhythm A, European Association for Cardio-Thoracic S, and A.J. Camm Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Eur. Heart J. 31 2010 2369 2429
39. L. Friberg, M. Rosenqvist, and G.Y. Lip Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study Circulation 125 2012 2298 2307
40. P. Gentilini, G. Laffi, and G. La Villa Long course and prognostic factors of virus-induced cirrhosis of the liver Am. J. Gastroenterol. 92 1997 66 72
41. P. Jepsen, P. Ott, P.K. Andersen, H.T. Sorensen, and H. Vilstrup Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study Hepatology 51 2010 1675 1682
42. C.S. Lieber Medical disorders of alcoholism N. Engl. J. Med. 333 1995 1058 1065
43. W. Blonski, T. Siropaides, and K.R. Reddy Coagulopathy in liver disease Curr. Treat. Options Gastroenterol. 10 2007 464 473